Compass Pathways cuts 30% of workforce on Phase 3 trial delays
The Fly

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways (CMPS) announced yesterday morning with earnings that as a result of changing timelines for its Phase 3 trials, it will be reducing its workforce by approximately 30%, including eliminating some senior management positions, “to further focus the organization and its capital resources on successfully delivering the COMP360 program.” The company’s non-COMP360 preclinical efforts will be stopped and it is “exploring a potential externalization” for its digital health tools.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App